

30 November 2018

NSX Announcement

UPDATE ON TRANSACTION DOCUMENTS WITH CYSTEMIX

Further to our announcement on 1 August 2018, Beroni Group Limited (NSX: BTG) ("Beroni" or the "Company") advises that it is currently finalising the share subscription and shareholders agreement ("Transaction Documents") with NewSouth Innovations Pty Ltd, a subsidiary of the University of New South Wales and Cystemix Pty Limited ("Cystemix").

Beroni will invest in Cystemix to advance the latter's clinical development of the potentially groundbreaking anti-cancer drug called PENAO. A total of \$10 million will be invested through tranches for 40% shares in Cystemix by the end of Phase II clinical trial of PENAO. Beroni will also be granted a right to acquire a further 11% shares in Cystemix during the period commencing when 50% patient enrolment of a Phase II trial and ending within 2 months after Phase II trial completion date for \$5.5 million.

The Transaction Documents are expected to be finalised and signed in December 2018.

Beroni will announce material information of the transaction documents when they are completed.

For further information please contact:

Mr Jacky Zhang
Executive Chairman

Tel: +86 1851 6931 911

E: jacky.zhang@beronigroup.com

Mr Peter Wong

Executive Director & CFO

Tel: +61 423 727 580

E: pwong@beronigroup.com

About Beroni Group Limited (NSX:BTG)

Beroni Group is an international biotechnological company listed on the National Stock Exchange of Australia. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases.

Beroni Group's overall strategic goal is to become a world's leading enterprise in the biotechnology, life sciences and environmental science industries.